看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
w- G0 \& [4 P1 ^. `% m/ E* {+ ] ~9 n$ l5 K3 {) q+ u
' g" ]8 F9 o+ d7 ]* FCurrently available feasibility data for possible combination strategies. ) D* F/ ~! M" ~; G' S
————————————————————————————————5 a# a2 D: ?) |* O. Z1 X& N
Combination Feasibility according to preliminary data 2 R" @* Y0 y; F) f ^. F
——————————————————————————————————
5 P' C: e+ U* P6 T2 [. o8 XBevacizumab + sorafenib Yes, reduced dose
: E2 w6 |) M6 tBevacizumab + sunitinib† No
5 J* V# w" p6 v7 m+ f. SBevacizumab + temsirolimus Yes
/ D; M1 z% \3 J: c% z: q. ?5 lBevacizumab + everolimus Yes 1 d6 p* Y; S: L9 d7 {( y- V
Sorafenib + sunitinib ?
1 Y+ s' k4 Q0 S, R& FSorafenib + temsirolimus Yes, reduced dose
* }7 b r! m# n0 s* FSorafenib + everolimus Yes, reduced dose / ?% R' f: ?+ t5 j( X$ g
Sunitinib + temsirolimus† No
+ y- w! ~+ G Z' j9 ?Sunitinib + everolimus ? " t4 @3 X9 s5 v; o
Temsirolimus + everolimus ?
- D; c: {0 F' @5 S8 i+ }/ p& v————————————————————
8 W" n2 U6 Q: r( O r1 ]†Led to US FDA warning.3 a m4 P' p; m; w- E6 I
?: As yet unattempted combination.
8 e) B# L- D/ Z/ C% m |
显身卡
